```html

Zollinger‑Ellison‑related Diarrhoea

What is Zollinger‑Ellison‑related diarrhoea?

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of gastric acid. The resulting hyper‑acidic environment can overwhelm the small intestine’s ability to neutralise acid, leading to malabsorption and watery, often profuse, diarrhoea. When the diarrhoea is directly linked to the high gastric acid output caused by ZES, it is referred to as Zollinger‑Ellison‑related diarrhoea.

Patients typically describe the stool as loose, fatty (steatorrhea), and foul‑smelling. The diarrhoea can be intermittent or chronic and may be accompanied by abdominal cramping, nausea, and weight loss. Because ZES is uncommon—affecting roughly 1 in 100,000 people—many clinicians first consider more common causes of diarrhoea before connecting it to a gastrinoma.

Common Causes

While the primary driver of this type of diarrhoea is excess gastric acid from a gastrinoma, several other conditions or factors can produce a similar clinical picture. Knowing these helps clinicians rule out alternatives and determine the right treatment plan.

• Gastrinomas (Zollinger‑Ellison syndrome) – the direct cause.
• Pancreatic neuroendocrine tumors (non‑gastrinoma) – can secrete other hormones that affect gut motility.
• Peptic ulcer disease with high acid output – severe hyperacidity can impair intestinal pH balance.
• Acid‑secreting gastric carcinoids – rare neuroendocrine tumors that also raise gastrin.
• Chronic use of proton‑pump inhibitor (PPI) rebound hyperacidity – sudden cessation may transiently increase acid production.
• Infectious diarrhoea (e.g., Clostridioides difficile, Giardia) – can mimic steatorrhea when malabsorption occurs.
• Inflammatory bowel disease (IBD) – Crohn’s disease of the small intestine can cause fatty diarrhoea.
• Pancreatic exocrine insufficiency – reduced lipase leads to fat malabsorption, producing similar stools.
• Short bowel syndrome – loss of absorptive surface post‑surgery.
• Medication‑induced diarrhoea – antibiotics, metformin, or laxatives can exacerbate symptoms.

Associated Symptoms

Because the diarrhoea stems from an acidic, malabsorptive environment, patients often notice a cluster of other complaints:

• Abdominal pain or cramping – usually epigastric, worsening after meals.
• Acid reflux or heartburn – due to overwhelming gastric acid.
• Nausea & vomiting – sometimes with a sour taste.
• Weight loss – from both caloric loss in stool and reduced intake.
• Steatorrhea – pale, bulky, foul‑smelling stools that float.
• Fatigue – secondary to electrolyte loss and malnutrition.
• Glossitis or oral ulceration – acid irritation of the mouth.
• Kidney stones – hypercalciuria can accompany ZES.

When to See a Doctor

The presence of diarrhoea alone rarely signals an emergency, but certain patterns demand prompt medical evaluation:

• Diarrhoea persisting > 2 weeks without an obvious cause.
• Severe abdominal pain that is constant or worsening.
• Unintentional weight loss > 5 % of body weight in a month.
• Signs of dehydration – dizziness, dry mouth, reduced urine output.
• Blood or black/tarry stool.
• Persistent vomiting or inability to keep fluids down.
• History of a diagnosed gastrinoma or unexplained high gastrin levels.

If any of these occur, schedule an appointment promptly or seek urgent care.

Diagnosis

Diagnosing Zollinger‑Ellison‑related diarrhoea involves confirming both the excess acid state and the presence of a gastrinoma.

1. Clinical Evaluation

• Detailed history focusing on stool characteristics, timing with meals, medication use, and any known endocrine tumors.
• Physical exam for abdominal tenderness, signs of malnutrition, or skin lesions (e.g., peptic ulcer scar).

2. Laboratory Tests

• Fasting serum gastrin – Levels > 1000 pg/mL are highly suggestive of ZES (Mayo Clinic).
• Secretin stimulation test – Gastrin rises > 120 pg/mL after IV secretin in gastrinoma patients (NIH guidelines).
• Basic metabolic panel – assesses electrolyte disturbances (e.g., hypokalemia, metabolic alkalosis).
• Fecal fat quantification – verifies steatorrhea.
• Stool cultures or PCR – to rule out infectious etiologies.

3. Imaging

• Endoscopic ultrasound (EUS) – high sensitivity for small pancreatic/duodenal lesions.
• Multiphasic contrast CT or MRI – maps tumor size and metastasis.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – detects neuroendocrine tumors that express somatostatin receptors.

4. Endoscopy

• Upper endoscopy (EGD) may reveal multiple duodenal ulcers, which are a hallmark of ZES.

5. Additional Evaluations

• Bone densitometry – chronic hypergastrinaemia can affect calcium balance.
• Renal ultrasound – to screen for nephrolithiasis.

Treatment Options

Therapy focuses on two goals: controlling gastric acid secretion and managing the underlying tumor.

Acid‑Suppression Therapy

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole 40–80 mg daily, esomeprazole 40–80 mg, or equivalent. PPIs are the cornerstone; most patients achieve symptom relief within days (Cleveland Clinic).
• Histamine‑2 receptor antagonists (H2RAs) – may be added for breakthrough symptoms, but are less effective alone.
• Long‑term PPI use requires monitoring for magnesium, vitamin B12, and calcium deficiencies.

Tumor‑Directed Treatments

• Surgical resection – Preferred for localized gastrinomas; can be curative in 60–70 % of cases.
• Somatostatin analogues (e.g., octreotide, lanreotide) – Inhibit gastrin release and control symptoms, especially in metastatic disease.
• Targeted therapies – Everolimus or sunitinib for progressive neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive tumors.
• Chemotherapy – Rarely needed; reserved for high‑grade neuroendocrine carcinomas.

Supportive & Home Management

• Hydration – Oral rehydration solutions or electrolyte‑rich fluids to replace losses.
• Dietary adjustments – Small, low‑fat meals; avoid caffeine, alcohol, and spicy foods that stimulate acid release.
• Pancreatic enzyme supplements – May reduce steatorrhea when exocrine insufficiency co‑exists.
• Probiotics – May improve gut flora and lessen diarrhoea frequency (Cochrane review, 2022).
• Vitamin & mineral supplementation – Especially magnesium, calcium, and B12 if on chronic PPI therapy.

Prevention Tips

While the development of a gastrinoma cannot be prevented, patients can minimise diarrhoea episodes and protect overall gut health:

• Take PPIs exactly as prescribed; never stop abruptly without a taper plan.
• Maintain a balanced diet low in saturated fat and high in soluble fiber (Mayo Clinic).
• Stay well‑hydrated—aim for at least 2 L of fluid per day, more if diarrhoea is active.
• Avoid nicotine and excessive alcohol, both of which increase gastric acid secretion.
• Schedule regular follow‑up labs to monitor electrolytes and nutrient levels.
• If you have a known gastrinoma, adhere to surveillance imaging schedules to detect recurrence early.
• Vaccinate against common enteric pathogens (e.g., rotavirus, norovirus) to reduce superimposed infections.

Emergency Warning Signs

Summary

Zollinger‑Ellison‑related diarrhoea is a distinct presentation of chronic, fatty diarrhoea driven by excessive gastric acid from gastrin‑secreting tumors. Prompt recognition, accurate diagnostic testing (fasting gastrin, secretin stimulation, imaging), and aggressive acid suppression are essential to improve quality of life and prevent complications such as malnutrition, kidney stones, and ulcer disease. Ongoing surveillance for tumor progression, combined with lifestyle measures and patient education, empowers individuals to manage this rare but treatable condition effectively.

For more detailed information, consult reputable sources such as the Mayo Clinic, the CDC, the NIH, and the Cleveland Clinic.

```